Asarina Pharma AB (publ) Year-end Report 2021 released
Peter Nordkild, CEO: “We enter the new financial year with renewed energy and optimism after Region Hovedstaden finally signed the required papers for our clinical test sites in Copenhagen, and we achieved ‘First Patient First Visit’ on 16 February in our phase IIa clinical study in Tourette syndrome. We are now moving ahead confidently in our search to develop a safer, entirely novel modality of treatment for Tourette syndrome, and, potentially, OCD.”
FINANCIAL HIGHLIGHTS
- Total operating expenses in Q4/21 reduced to 8.7 MSEK (24.9 MSEK in Q4/20)
- Cash balance at 31 December 2021 amounted to 21.7 MSEK, which will be sufficient to fund the Tourette Study
R&D HIGHLIGHTS
TOURETTE SYNDROME
The Capital Region of Denmark (Region Hovedstaden) was finally able to sign the clinical trial agreements for the two study sites in Copenhagen.
On 16 February 2022, ‘First Patient First Visit’ took place in the phase IIa study in Tourette syndrome, with the first patient randomized on 17 February.
OCD
Following the US patent granted to Sepranolone for the treatment of OCD, we have continued to explore possibilities for funding of a clinical study on a potential new combination therapy of Sepranolone, together with SSRIs, for OCD. Tourette is highly co-morbid – 86% of patients have at least one additional disorder, with OCD being particularly prevalent.
To read the Report in full please visit: https://asarinapharma.com/investors/financial-reports/
